Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, EMERGENT BIOSOLUTIONS INC. reported revenue of $743M, down 28.8% year over year. Operating margin was 13.5% and net margin 7.1%, on a free-cash-flow margin of 21.1% with capital expenditure at 1.9% of revenue. Every figure is computed directly from EBS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $743M | 13.5% | 7.1% |
| FY2024 | $1.04B | -10.4% | -18.3% |
| FY2023 | $1.05B | -69.2% | -72.5% |
| FY2022 | $1.12B | -15.2% | -18.9% |
| FY2021 | $1.77B | 19.2% | 12.4% |
How does EBS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.